This finding adds support for VMAT2 inhibitors as a promising option for psychiatric patients with TD; not only do VMAT2 inhibitors enable control of TD symptoms without necessitating changes to pharmacotherapy for the underlying psychiatric condition, but they do so without changes in psychiatric stability. Here, SLC18A2 is linked to thanatophoric dysplasia.